Bayer may have to sell assets to pay for Roundup cancer suits
Bayer is facing 48,600 US plaintiffs with its shares down 31% since the $63bn takeover of Monsanto, which brought it the herbicide Roundup
27 February 2020 - 18:03
Munich — Bayer has acknowledged for the first time that lawsuits related to the controversial weed killer Roundup could force it to sell assets, issue new equity, or borrow money at unfavourable terms.
In its annual report published on Thursday, Bayer said that it “may incur considerable financial disadvantages” from pending suits as well as future cases from US plaintiffs who say the herbicide causes cancer...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.